Apellis Pharms Drug Patent Portfolio

Apellis Pharms's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Apellis Pharms News

Novo Nordisk Secures New Complement System Strategy for Rare Diseases Through Agreement for Omeros Medication

15 Oct, 2025

Madrigal invests in GLP-1 through CSPC; Apellis receives broader drug approval.

31 Jul, 2025

Purchase Recommendation Maintained for Apellis Pharmaceuticals' Syfovre, Expected to Achieve Blockbuster Status Despite ...

02 Aug, 2024

See More